The Medicines Company Seeks To Sharpen Angiomax Label With ACUITY Data
This article was originally published in The Pink Sheet Daily
Executive Summary
An acute coronary syndromes claim based on ACUITY would open up nearly 2 million additional potential patients per year for the anticoagulant, COO Kelley tells “The Pink Sheet” DAILY.
You may also be interested in...
Angiomax “Not Approvable” For Acute Coronary Syndromes
The Medicines Company says FDA letter is "vague"; concerns pertain to non-inferiority design for ACUITY trial.
Angiomax “Not Approvable” For Acute Coronary Syndromes
The Medicines Company says FDA letter is "vague"; concerns pertain to non-inferiority design for ACUITY trial.
The Medicines Company Aims For Mid-2008 Cleviprex Launch
The third-generation, acute care calcium channel blocker’s FDA user fee date is in May 2008, COO Kelley tells “The Pink Sheet” DAILY.